These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 29077839)

  • 21. Antibiotics for induction and maintenance of remission in Crohn's disease.
    Townsend CM; Parker CE; MacDonald JK; Nguyen TM; Jairath V; Feagan BG; Khanna R
    Cochrane Database Syst Rev; 2019 Feb; 2(2):CD012730. PubMed ID: 30731030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
    Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
    J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimal doses of methotrexate combined with anti-TNF therapy to maintain clinical remission in inflammatory bowel disease.
    Colman RJ; Rubin DT
    J Crohns Colitis; 2015 Apr; 9(4):312-7. PubMed ID: 25616487
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adalimumab Drug Levels at Secondary Loss of Response Do Not Predict Response to Dose-intensification in Crohn's Disease: A Retrospective, International Multicenter Study.
    Little RD; Swaine A; Reynolds R; Gibson DJ; Barrau M; D'Errico F; Hampal R; Sparrow MP; Roblin X; Irving PM; Ward MG
    Inflamm Bowel Dis; 2024 Oct; 30(10):1714-1723. PubMed ID: 37951220
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-TNF Therapy Within 2 Years of Crohn's Disease Diagnosis Improves Patient Outcomes: A Retrospective Cohort Study.
    Ma C; Beilman CL; Huang VW; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    Inflamm Bowel Dis; 2016 Apr; 22(4):870-9. PubMed ID: 26818419
    [TBL] [Abstract][Full Text] [Related]  

  • 26. De-escalation of Infliximab Maintenance Therapy from 8- to 10-week Dosing Interval Based on Faecal Calprotectin in Patients with Crohn's Disease.
    Papamichael K; Karatzas P; Mantzaris GJ
    J Crohns Colitis; 2016 Mar; 10(3):371-2. PubMed ID: 26546496
    [No Abstract]   [Full Text] [Related]  

  • 27. Does weight-adjusted anti-tumour necrosis factor treatment favour obese patients with Crohn's disease?
    Bhalme M; Sharma A; Keld R; Willert R; Campbell S
    Eur J Gastroenterol Hepatol; 2013 May; 25(5):543-9. PubMed ID: 23337170
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy.
    Sands BE; Sandborn WJ; Van Assche G; Lukas M; Xu J; James A; Abhyankar B; Lasch K
    Inflamm Bowel Dis; 2017 Jan; 23(1):97-106. PubMed ID: 27930408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravenous Versus Subcutaneous Anti-TNF-Alpha Agents for Crohn's Disease: A Comparison of Effectiveness and Safety.
    Liu J; Sylwestrzak G; Ruggieri AP; DeVries A
    J Manag Care Spec Pharm; 2015 Jul; 21(7):559-66. PubMed ID: 26108380
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spacing the Administration Interval of Anti-TNF Agents: A Valid Strategy for Patients with Inflammatory Bowel Disease?
    Torres P; Cañete F; Núñez L; Aguilar A; Mesonero F; Calafat M; Fernández C; Teniente A; Mañosa M; López-Sanromán A; Domènech E
    Dig Dis Sci; 2020 Jul; 65(7):2036-2043. PubMed ID: 31858325
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonists in patients with Crohn's disease.
    Boschetti G; Garnero P; Moussata D; Cuerq C; Préaudat C; Duclaux-Loras R; Mialon A; Drai J; Flourié B; Nancey S
    Inflamm Bowel Dis; 2015 Feb; 21(2):331-6. PubMed ID: 25625487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating Interleukin 6 and Albumin, and Infliximab Levels Are Good Predictors of Recovering Efficacy After Dose Escalation Infliximab Therapy in Patients with Loss of Response to Treatment for Crohn's Disease: A Prospective Clinical Trial.
    Suzuki Y; Matsui T; Ito H; Ashida T; Nakamura S; Motoya S; Matsumoto T; Sato N; Ozaki K; Watanabe M; Hibi T
    Inflamm Bowel Dis; 2015 Sep; 21(9):2114-22. PubMed ID: 26218144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease.
    Walters TD; Kim MO; Denson LA; Griffiths AM; Dubinsky M; Markowitz J; Baldassano R; Crandall W; Rosh J; Pfefferkorn M; Otley A; Heyman MB; LeLeiko N; Baker S; Guthery SL; Evans J; Ziring D; Kellermayer R; Stephens M; Mack D; Oliva-Hemker M; Patel AS; Kirschner B; Moulton D; Cohen S; Kim S; Liu C; Essers J; Kugathasan S; Hyams JS;
    Gastroenterology; 2014 Feb; 146(2):383-91. PubMed ID: 24162032
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimized thiopurine therapy before withdrawal of anti-tumour necrosis factor-α in patients with Crohn's disease.
    Bohn Thomsen S; Kiszka-Kanowitz M; Theede K; Gluud LL; Mertz Nielsen A
    Eur J Gastroenterol Hepatol; 2018 Oct; 30(10):1155-1158. PubMed ID: 29975242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.
    Absah I; Faubion WA
    Inflamm Bowel Dis; 2012 Aug; 18(8):1488-92. PubMed ID: 21882301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early Initiation of Tumor Necrosis Factor Antagonist-Based Therapy for Patients With Crohn's Disease Reduces Costs Compared With Late Initiation.
    Beilman CL; Kirwin E; Ma C; McCabe C; Fedorak RN; Halloran B
    Clin Gastroenterol Hepatol; 2019 Jul; 17(8):1515-1524.e4. PubMed ID: 30056180
    [TBL] [Abstract][Full Text] [Related]  

  • 37. De-escalation from Dose-Intensified Anti-TNF Therapy Is Successful in the Majority of IBD Patients at 12 Months.
    Little RD; Chu IE; Ward MG; Sparrow MP
    Dig Dis Sci; 2022 Jan; 67(1):259-262. PubMed ID: 33763785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trefoil factor-3 is not a useful marker of mucosal healing in Crohn's disease treated with anti-TNF-α antibodies.
    Eder P; Stawczyk-Eder K; Korybalska K; Czepulis N; Luczak J; Lykowska-Szuber L; Krela-Kazmierczak I; Linke K; Witowski J
    World J Gastroenterol; 2017 Jan; 23(1):135-140. PubMed ID: 28104989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Continental Divide: Anti-TNF Use in Pediatric IBD Is Different in North America Compared to Other Parts of the World.
    Church PC; Hyams J; Ruemmele F; de Ridder L; Turner D; Griffiths AM
    Can J Gastroenterol Hepatol; 2018; 2018():3190548. PubMed ID: 30009157
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thiopurines and their optimization during infliximab induction and maintenance: A retrospective study in Crohn's disease.
    Luber RP; Dawson L; Munari S; Kariyawasam VC; Martin C; Gibson PR; Sparrow MP; Ward MG
    J Gastroenterol Hepatol; 2021 Apr; 36(4):990-998. PubMed ID: 32881046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.